



**DIVERSE BIOMOLECULES PRESENT IN ETHANOLIC EXTRACT OF FRUITS OF
PUNICA GRANATUM L(EEF-PG) ACT AS POTENTIAL HEPATOCYTES
REGENERATOR**

Asish Bhaumik^{1*}, SK. Nagulmeera¹, G. Neelamma², Sanjoy Das³ and K. Sreelatha⁴

^{1,4}Department of Pharmaceutical Chemistry, Teja College of Pharmacy, Kodad, Nalgonda-508206, Telangana State, India.

²Research Scholar, Department of Pharmacognosy and Phytopharmacy, JSS College of Pharmacy, Ooty-643001, Tamil Nadu, India.

³Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, Pin-786004, India.

***Correspondence for Author: Asish Bhaumik**

Department of Pharmaceutical Chemistry, Teja College of Pharmacy, Kodad, Nalgonda-508206, Telangana State, India.

Article Received on 23/02/2016

Article Revised on 14/03/2016

Article Accepted on 04/04/2016

ABSTRACT

Punica granatum is grown as a fruit crop plant, and as ornamental trees and shrubs in parks and gardens. The edible fruit of *Punica granatum* is a berry and is between a lemon and a grapefruit in size, 5–12 cm in diameter with a rounded hexagonal shape and has thick reddish skin. The main aim and objectives of the present work was to isolate the bioactive molecules from the ethanolic extract of fruits *Punica granatum* (EEF-PG) and evaluate the *in vivo* hepatoprotective activity. The isolation and characterization of biomolecules was carried out by ESI-MS-MS. *In vivo* hepatoprotective activity was performed against CCl₄ induced rat hepatocytes. The Results displayed that the elevated levels of SGOT, SGPT, ALP and Serum bilirubin due to CCl₄ intoxication were reduced significantly (*P<0.05) in rats, after treatment with EEF-PG. Treatment with EEF-PG at a both doses of 200 and 400 mg/kg b.w. significantly decreased the SGOT, SGPT, ALP, Serum Bilirubin levels by 10.76%, 23.30%, 10.18% and 36.98% (at low dose) and 25.33%, 42.26%, 22.66% and 54.79% (at high dose) respectively. Silymarin used as standard drug showed a reduction of 74.19%, 76.91%, 86.7% and 78.08% receiving CCl₄ alone. So depending upon the experimental evidence, it was confirmed that the biochemical parameters of the group treated with EEF-PG was significantly lower than the CCl₄-treated group. Histopathological examination of liver section of the rat treated with both 200 mg/kg, 400 mg/kg body weight of EEF-PG intoxicated with carbon tetrachloride had shown minimal inflammation with moderate portal triditis, moderate necrotic debris, centrilobular regeneration with restoration of central vein, sinusoids and hepatocytes with mild necrosis and their lobular architecture was normal.

KEYWORDS: Bioactive molecules, Hepatoprotective activity, ESI-MS-MS, Portal triditis, centrilobular regeneration etc.

INTRODUCTION

The *Punica granatum* leaves are opposite or sub-opposite, glossy, narrow oblong, entire, 3–7 cm long and 2 cm broad. The flowers are bright red, 3 cm in diameter, with four to five petals (often more on cultivated plants). Some fruitless varieties are grown for the flowers alone. The edible fruit is a berry and is between a lemon and a grapefruit in size, 5–12 cm in diameter with a rounded hexagonal shape, and has thick reddish skin. The exact number of seeds in a pomegranate can vary from 200 to about 1400 seeds, contrary to some beliefs that all pomegranates have exactly the same number of seeds.^[1] Each seed has a surrounding water-laden pulp—the edible sarcotesta that forms from the seed coat—ranging in color from white to deep red or purple. The seeds are embedded in a white, spongy, astringent membrane.^[2]

The preliminary phytochemical screening displayed the present of following phytoconstituents in *Punica granatum*: Energy -346 kJ (83 kcal), Carbohydrates (18.7 g), Sugars (13.67 g), Dietary fiber (4 g) Fat (1.17 g), Protein (1.67 g), Thiamine (vit. B1) - 0.067 mg (6%), Riboflavin (vit. B2) 0.053 mg (4%), Niacin (vit. B3) - 0.293 mg (2%), Pantothenic acid (B5) - 0.377 mg (8%), Vitamin B6 - 0.075 mg (6%), Folate (vit. B9) - 38 µg (10%), Choline - 7.6 mg (2%), Vitamin C - 10.2 mg (12%), Vitamin E - 0.6 mg (4%), Vitamin K - 16.4 µg (16%), Calcium - 10 mg (1%), Iron - 0.3 mg (2%), Magnesium - 12 mg (3%), Manganese - 0.119 mg (6%), Phosphorus - 36 mg (5%), Potassium - 236 mg (5%), Sodium - 3 mg (0%), Zinc - 0.35 mg (4%). Pomegranate seeds provide 12% of the Daily Value (DV) for vitamin C and 16% DV for vitamin K per 100 g serving, and

contain polyphenols, such as ellagitannins and flavonoids. Pomegranate seeds are excellent sources of dietary fiber which is entirely contained in the edible seeds. People who choose to discard the seeds forfeit nutritional benefits conveyed by the seed fiber and micronutrients.^[3,4]

In preliminary laboratory research and clinical trials, juice of the pomegranate may be effective in reducing heart disease risk factors, including LDL oxidation, macrophage oxidative status, and foam cell formation.^[5,6,7] In mice, "oxidation of LDL by peritoneal macrophages was reduced by up to 90% after pomegranate juice consumption.^[8] In a limited study of hypertensive patients, consumption of pomegranate juice for two weeks was shown to reduce systolic blood pressure by inhibiting serum angiotensin-converting enzyme.^[9] Juice consumption may also inhibit viral infections^[10], while pomegranate extracts have antibacterial effects against dental plaque.^[11] Metabolites of pomegranate juice ellagitannins localize specifically in the prostate gland, colon, and intestinal tissues of mice^[12], leading to clinical studies of pomegranate juice or fruit extracts for efficacy against several diseases. In 2013, 44 clinical trials were registered with the National Institutes of Health to examine effects of pomegranate extracts or juice consumption on a variety of human disorders, including^[13]: prostate cancer, prostatic hyperplasia, diabetes, lymphoma, rhinovirus infection, common cold, oxidative stress in diabetic hemodialysis, atherosclerosis, coronary artery disease, infant brain injury, hemodialysis for kidney disease, male infertility, aging, memory, pregnancy complications, osteoporosis and erectile dysfunction. One pilot study in adult subjects found that daily consumption of pomegranate juice over two weeks increased salivary testosterone levels by 24% and had other effects on blood pressure, mood, anxiety or emotions.^[14]

MATERIALS AND METHOD

Drugs and chemicals

The all chemicals used for the extraction and phytochemical screening were of LR and AR grade. Standard drugs silymarin was purchased from Local

Retail Pharmacy Shop and solvents and other chemicals were used from Institutional Store and were of AR grade.

Instrumentation

The Polyphenols present in EEF-PG were determined by ESI-MS/MS. The pomegranate fruits extract was analyzed using a Waters Quattro Premier XE tandem quadrupole mass spectrometer equipped with electro-spray ionization (ESI) source.

Experimental animals

White male albino Wister rats weighing about 200-250 g was used. They were obtained from the animal house of C.L. Baid Metha College of Pharmacy, Chennai. They were kept under observation for about 7 days before the onset of the experiment to exclude any intercurrent infection, had free access to normal diet and water. The animals were housed in plastic well aerated cages at normal atmospheric temperature ($25\pm 5^\circ\text{C}$) and normal 12- hour light/dark cycle under hygienic conditions. The experimental protocol was approved by Institutional Animal Ethics Committee (IAEC) of CPCSEA: IAEC/XXIX/12/2015.

CHEMISTRY

Methodology for extraction

Weigh 20 g of fruits of *Punica granatum* paste (ripen can be mashed to prepare a paste) into a 250 ml round-bottomed flask. Add 50 ml of ethanol and 60 ml of dichloromethane. Heat the mixture under reflux for 5 min on steam-bath with frequent shaking. Filter the mixture under suction and transfer the filtrate to a separatory funnel. Wash this mixture containing bioactive compounds with three portions of 150 ml each with sodium chloride solution. Dry the organic layer over anhydrous magnesium sulfate.^[15] Filter and evaporate most of the solvent in vacuum without heating and obtained ethanolic extract of fruits of *Punica granatum* (EEF-PG).




Fig 1: Ethanolic Extract of fruits of *Punica granatum* (EEF-PG).

Phytochemical screening^[16,17,18]

Preliminary Phytochemical screening of ethanolic extract of fruits of *Punica granatum* L (**EEF-PG**) had shown the presence of various bioactive compounds such as carbohydrates, aminoacids and peptides, phytosterols, carotenoids, and polyphenols etc.

Characterization of biomolecules present in EEF-PG

The Polyphenols present in EEF-PG were determined by ESI-MS/MS. The pomegranate fruits extract was analyzed using a Waters Quattro Premier XE tandemquadrupole mass spectrometer equipped with electro-spray ionization (ESI) source. Instrument control and data acquisition were performed using Mass Lynx ver. 4.1 software. The instrument was calibrated for nominal resolution for MS1 and MS2 up to 1200 m/z using the sodium cesium iodide standard calibration solution. The sample was introduced by direct infusion at a flow rate of 40 μ L/min and was run in both positive and negative ionization mode for the preliminary screening (full scan mode) from 50 m/z to 1200 m/z. The compounds of interest were tuned by optimizing the sample cone voltage (20-50 V) and a capillary voltage to 3.5 KV in order to observe the bioactive substances most amenable to electro spray ionization. The parent ions of the compounds of interest were then subjected to tandem MS analysis using the daughter scan function using the following tuning parameters: (ESI), capillary voltage set between 3.3 to 3.6 KV, cone voltage (30 V), extractor (3 V), RF Lens (0.2 V), source temperature (100°C), dissolution temperature (150°C), multiplier (650 V), the collision energy was optimized in the range from 20 to 45 eV. Most of the daughter peaks were identified by matching the fragmentation patterns obtained from the daughter scan to those theoretically and experimentally documented in literature.^[19-31]

PHARMACOLOGY**Protocol for the study of acute oral toxicity of EEF-PG**

In the present study the acute oral toxicity of the ethanolic extract of fruits of *Punica granatum* was performed by acute toxic class method. In this method the toxicity of the extract was planned to test using step wise procedure, each step using three Wister rats. The rats were fasted prior to dosing (food but not water should be withheld) for three to four hrs. Following the period of fasting the animals were weighed and the extract was administered orally at a dose of 2000 mg/Kg b.w. Animals were observed individually after dosing at least once during the first 30 min; periodically the surveillance was carried out for the first 24 hrs with special attention given during the first 4 hrs and daily thereafter, for a total of 14 days.^[32]

Experimental protocol for the evaluation of *in vivo* hepatoprotective activity^[33]

A total of 30 rats were taken and divided into 5 groups of 6 rats each

(A) **Group I:** Normal Control Group [**NCG** - (only the

vehicle (1 mL/kg/day of 1% CMC; p.o.)].

(B) **Group II:** Negative Control Group [**Neg.CG** - (CCl₄ 1 mL/kg (1:1 of CCl₄ in olive oil) i. p)].

(C) **Group III:** Positive Control/Standard Group [**SG** - CCl₄ 1 mL/kg (1:1 of CCl₄ in olive oil) i.p.+ Standard Silymarin 100 mg/kg orally (p.o.) for 7 days]

Treatment Groups

(D) **Group V:** Low Dose Group [**LDG** - CCl₄ 1 mL/kg (1:1 of CCl₄ in olive oil) i. p + **EEF-PG** (200 mg/ kg b. w., p.o.)]. Treatment was given daily for seven days orally.

(E) **Group IV:** High Dose Group [**HDG** - CCl₄ 1 mL/kg (1:1 of CCl₄ in olive oil) i.p + **EEF-PG** (400 mg/ kg b. w., p.o.)].

Collection of blood

On the 8th day, blood was collected by retro orbital puncture, under mild ether anesthesia after 8 hr fasting. Blood samples were centrifuged at 3000 rpm for 20 mins. Serum was separated and stored at - 200°C until biochemical estimations.

Biochemical Analysis

The Serum sample was taken for the determination of SGOT, SGPT, SALP and Serum bilirubin etc.

RESULTS AND DISCUSSION**Phytochemical screening**

Preliminary Phytochemical screening of ethanolic extract of fruits of *Punica granatum* L (**EEF-PG**) had shown the presence of various bioactive compounds such as carbohydrates, aminoacids and peptides, phytosterols, carotenoids, and polyphenols which are ascertained by their qualitative confirmatory tests.

Characterization of biomolecules by ESI-MS/MS

The present study demonstrated the fractionation of pomegranate fruit in ethyl acetate as a solvent which was very efficient in exhibiting various compounds of polyphenols when subjected to the ESI-MS/MS analysis. ESI-MS/MS spectra of the direct infusion of *Punica* ethyl acetate fraction showed the presence of wide array of phenolic compounds. The main constituents of ethyl acetate fraction were monitored by diode-array and mass spectrometry. Typical direct infusion mass spectra of phenolic compounds of interest from the pomegranate fruit extract are shown in **Fig 1-5. Table: 1** outlines the peak list for the full scan (precursor ions) and daughter scan (product ions) mass spectra for the major compounds of interest. The profile of the extract showed 16 major phenolic compounds and several derivatives. The phenolic compounds were classified into three categories: hydroxycinnamic acids, hydrolysable tannins and hydroxybenzoic acids. Peak identities were obtained by matching their pseudo molecular ions [M-H] - obtained by ES/MS and tandem MS with the expected theoretical molecular weights from literature. It is evident that various antioxidant substances are present in pomegranate fruits. In addition, the fruits contain

significant amounts of ellagitannins, such as punicalin (Compound 22) and punicalagin (Compound 26) together with hexahydroxydiphenic acid (HHDP) derivatives (Compounds 23 & 24) and flavonoids such as

quercetin (Compound 17) as well as the ellagic acid (Compounds 14,19) and gallic acid derivatives (Compounds 27-35).




Fig 1




Fig 2




Fig 3




Fig 4




Fig 5

Table 1: for Characteristic ions of phenolic compounds of pomegranate fruit extract




Compound	Assignment	Chemical formula	[M-H]-m/z	MS-MSm/z
Hydroxycinnamic acid derivatives				
C1	Caffeic acid	C ₉ H ₈ O ₄	179	59, 71, 75, 89, 135
C2	Fragment of caffeic acid	C ₈ H ₈ O ₂	135	71, 75
C3	Fragment of caffeic acid	C ₈ H ₆ O ₄	165	59, 71, 75
C4	Caffeic acid derivative	C ₉ H ₁₀ O ₄	181	59, 71, 89
C5	Caffeic acid derivative	-	215	59, 71, 89, 179, 225
C6	Caffeic acid derivative	-	217	59, 71, 89, 179, 181
C7	Caffeic acid derivative	-	219	179
C8	Caffeic acid phenylester	C ₁₇ H ₁₆ O ₄	283	59, 179
C9	Methyl gallate derivative	-	325	169, 183
C10	Caffeoylquinic acid	C ₁₆ H ₁₈ O ₉	353	111, 129
C11	Caffeic acid derivative	-	457	179, 215
C12	P-Comaric acid glucuronide	C ₁₅ H ₁₆ O ₉	339	163
Hydrolysable tannins				
C13	Brevifolin carboxylic acid	C ₁₃ H ₈ O ₈	291	80, 247
C14	Ellagic acid	C ₁₄ H ₆ O ₈	301.13	185, 229, 257
C15	Galloyl-hex(glucogallin)	C ₁₃ H ₁₆ O ₁₀	331	125, 169
C16	Eschweilenol C	C ₂₀ H ₁₆ O ₁₂	447.17	432, 389, 77
C17	Quercetin-3-O-glucoside	C ₁₅ H ₁₀ O ₇	463	89, 265, 301
C18	HHDP-hex	C ₁₃ H ₁₈ O ₁₄	481.2	57, 275, 301, 180
C19	Ellagic acid der	-	515	229, 275, 301






C20	Galloyl-HHDP-hex	$C_{27}H_{22}O_{18}$	633	275, 301
C21	Galloyl-HHDP-gluconide Lagerstannin C	$C_{27}H_{22}O_{19}$	649	301
C22	Punicalin	$C_{34}H_{22}O_{22}$	781	601, 299, 300
C23	Bis-HHDP-hex Pedunculagin I	$C_{34}H_{24}O_{22}$	783	301, 602, 481
C24	Digalloyl-HHDP-hex Pedunculagin II	$C_{34}H_{26}O_{22}$	785	633
C25	Galloyl-HHDP- DHHDP- Glucoside GranatinB	$C_{34}H_{28}O_{27}$	951	481
C26	HHDP- gallagylglucoside Punicalagin	$C_{48}H_{28}O_{30}$	1083	781, 601, 602
Hydroxy benzoic acid				
C27	Gallic acid	$C_7H_6O_5$	169	69, 79, 83, 97, 110,
C28	Fragment of gallic acid	$C_6H_6O_3$	125	69, 79
C29	Gallic acid der	-	277	79, 97
C30	Gallic acid der	-	279	79, 97
C31	Gallic acid der	-	395	125, 169, 215
C32	Gallic acid der	-	397	127, 171, 181, 217
C33	Vanilic acid der	-	255	128, 167
C34	Protocatechuic acid der	-	435	79, 89, 153, 171
C35	Methyl gallate der	-	311	169, 183





The chemical structures of major identified compounds are represented in **Table: 2**. Several [M-H] - ions were detected in the extract of freeze-dried pomegranate fruit using a tandem mass spectrometry (MS/MS) equipped with electro-spray ionization (ESI) interface. This study represents the first phenolic analysis for pomegranate fruit and as far as we are aware also reports the identification of some molecular ions that have not been reported before such as caffeic acid derivatives m/z 215,


217, 283, methyl gallat ester, quinic acid methyl ester and hexahydroxydiphenic acid (HHDP)-acetyl glucoside derivatives. Due to the large number of detected ions and unavailability of authentic standards, identifications of all molecular ions were carried out by direct infusion analysis using the negative full scan mode and their structural information elucidated by performing a daughter scan on the molecular ion of interest.

Table: 2 for the chemical structures of major identified compounds

Sl. No.	Compounds
1.	 <p>Caffeic acid</p>
2.	 <p>Caffeoylquinic acid</p>
3.	 <p>p-comaric acid glucuronide.</p>

4.	 <p>Brevifolin carboxylic acid</p>
5.	 <p>Ellagic acid</p>
6.	 <p>Glucogallin</p>
7.	 <p>Eschweilenol-C</p>
8.	 <p>Quercetin-3-O-glucoside</p>

9.	 <p>Galloyl-HHDP-glucuronide-Lagerstanin C</p>
10.	 <p>Punicalin</p>
11.	 <p>Digalloyl-HHDP-hex-pedunculagin II</p>
12.	 <p>Galloyl-HHDP-DHHDP-glucoside gratin B</p>



Chemical structure of major compounds found in the fruits extract of *Punica granatum* using ESI-MS/MS analysis

Hydroxycinnamic acids

Compound 1 had [M-H]⁻ at m/z 179 which fragmented into MS 2 ion at m/z 135 (loss 44 u [COO]) and it was identified as caffeic acid. Compounds 2 -7 in **Table 1** were considered caffeic acid fragments and derivatives because they showed similar product ion spectra. The MS/MS fragmentation pathway of compound 8 at m/z 283 showed two fragments m/z 179 (loss of phenethyl alcohol group with m/z and with m/z 104 water 18 u) and m/z 59, so the compound was assigned as caffeic acid phenethyl ester. Compound 12 at m/z 339 was identified as p-comaric acid glucuronide because its further fragmentation lost glucuronic acid moiety (176 u) yielding the fragment m/z 163.

Hydrolysable tannins

A number of 14 metabolites were identified in this group. The predominant compound was ellagic acid at m/z 301 with fragments m/z 257, 229, 185. The efficacy of this important compound has been considered

atreatment for some low to mild and chronic disorders. Compound 13 was identified as brevifolin carboxylic acid at m/z 291 as its MS/MS fragmentation showed a [M-H-COO]⁻ fragment at m/z 247. The loss of 162 u and 18 u from m/z 481 to m/z 301 was most likely due to the breakdown of glucose and water, so this compound was identified as hexahydroxydiphenoyl - glucoside (HHDP - glucoside). Compounds 21- 26 exhibited [M-H]⁻ ions with m/z 633, 649,781, 783, 785, 951 and 1083. Their MS 2 fragmentations nearly led to the same basic structure and were all identified as Galloyl-HHDP-hex, Galloyl-HHDP-gluconidelagerstannin C, punicalin, bis-HHDP-hex pedunculagin 1, Digalloyl-HHDP-hexpedunculagin II, Galloyl- HHDP-DHHDP-glucosidegranatin B, and HHDP-gallagyl glucoside punicalagin.

Hydroxybenzoic acids

Four gallic acid derivatives were detected in the extract from the negative ionization mode at m/z 277, 279, 395 and 397 as their MS/MS fragments matched well with basic fragmentation of gallic acid. Beside gallic acid derivatives, vanilic acid and protocatechuic acid

derivatives were also detected with molecular ions m/z 255 and 435. A compound m/z 311 was characterized as methyl gallate derivative; this was because it showed two fragments m/z 183 and 169. The 14 u difference between the two fragments was due to the loss of CH_2 .

Acute oral toxicity study

- (i) Acute oral toxicity studies were performed according to the OECD guideline 423 method.
- (ii) This method has been designed to evaluate the substance at the fixed doses and provide information both for hazard assessment and substance to be ranked for hazard classification purposes.
- (iii) The **EEF-PG** was administered initially at a dose of 2000 mg/kg b.w and 1% CMC (p.o) and observed 14 days mortality due to acute toxicity.

(iv) Careful observation were made at least thrice a day for the effect on CNS, ANS, motor activity, salivation and other general signs of toxicity were also observed and recorded.

(v) Since no sign of toxicity observed at 2000 mg/kg b.w. to the group of animals, the LD_{50} value of the **EEF-PG** expected to exceed 2000 mg/kg b. w. and represented as class 5 (2000 mg/kg < LD_{50} < 2500 mg/kg).

(vi) From the toxicity studies the data revealed that all the synthesized compounds proved to be non toxic at tested dose levels and well tolerated by the experimental animals as there LD_{50} cut of values > 2000 mg/kg b. w.

Table 3: for the dose selection by acute toxicity class method (OECD) guide lines 423 of EECs

Sl. No.	Treatment group	Dose mg/kg	Sign of toxicity	Onset of toxicity	Duration
1	EE	200	No	No	14 days
2	EE	400	No	No	14 days

Evaluation of *In vivo* hepatoprotective activity

Statistical analysis: The data were expressed as mean \pm SD. Statistical differences at $*P < 0.05$ between the groups were analyzed by one-way ANOVA followed by Dunnett's Multiple Comparison Test using Graph Pad Prism 5.04 Instate software package. The data's were compared with group-II i. e. Negative Control group.

Biochemical analysis

The effects of **EEF-PG** on liver marker enzymes and serum bilirubin content are displayed in **Table 4**. The data exhibited that Normal Control Group demonstrated a normal range of AST, ALT and bilirubin levels while the CCl_4 -treated group showed elevated levels of AST, ALT and bilirubin, thus confirming that CCl_4 causes hepatocellular degeneration at higher doses. The elevation of cytoplasmic AST and ALT is considered an indicator for the release of enzymes from disrupted liver cells. Bilirubin concentration has been used to evaluate

chemically induced hepatic injury. The Results displayed in **Table 2 and Fig: 1-2** indicated that the elevated levels of SGOT, SGPT, ALP and Serum bilirubin due to CCl_4 intoxication were reduced significantly ($*P < 0.05$) in rats, after treatment with **EEF-PG**. Treatment with **EEF-PG** at a both doses of **200 and 400 mg/kg b.w.** significantly decreased the SGOT, SGPT, ALP, Serum Bilirubin levels by **10.76%, 23.30%, 10.18%, and 36.98% (at low dose) and 25.33%, 42.26%, 22.66% and 54.79% (at high dose)** respectively. Silymarin used as standard drug showed a reduction of **74.19%, 76.91%, 86.7% and 78.08%** receiving CCl_4 alone. So depending upon the data of **Table 1** it was confirmed that the biochemical parameters of the group treated with **EEF-PG** was significantly lower than the CCl_4 -treated group. Moreover the treatment with the **EEF-PG** significantly reduced the previously raised levels of AST, ALT, ALP and bilirubin in hepatotoxic rats.

Table: 4 for the assessment of Biochemical parameters

Sl. No	Treatment	AST(SGOT) IU/L	ALT(SGPT) IU/L	ALP(SALP) IU/L	Sr. bilirubin mg/dL
1.	NCG-I	52.25 \pm 0.3566	48.11 \pm 0.1533	51.95 \pm 0.1531	0.7268 \pm 0.0069
2.	Neg. CG-II	202.5 \pm 0.3038***	208.4 \pm 0.1961***	391.9 \pm 1.411***	7.383 \pm 0.1014***
3.	LDG-III	180.7 \pm 0.2176***	160.6 \pm 0.08021***	351.1 \pm 2.629***	4.665 \pm 0.039***
4.	HDG-IV	151.2 \pm 0.1461***	120.9 \pm 0.6005***	302.8 \pm 0.1769***	3.397 \pm 0.3531*
5.	SG-V	91.60 \pm 1.795***	109.8 \pm 6.818***	155.7 \pm 6.240***	0.9000 \pm 0.0577 ^{ns}




Fig 1: Comparison of sr. enzymes levels in different groups.




Fig 2: Comparison of sr. bilirubin level in different groups.

Histopathological Analysis

The results of light microscopy examination of the transverse section of control, CCl₄-treated and treated with **EEF-PG** rat livers were represented in **Fig 3 and 4**. It was revealed that the liver section of animals treated with CCl₄ showed a high degree of damage characterized by cell vacuolation, pyknotic and degenerated nuclei and wall of bile capillaries. The normal architecture of the liver was lost. The intralobular vein was badly damaged

with wide spaces at some sinusoids. Liver sections of these rats indicated necrosis, ballooning and degeneration in hepatic plates and loss of cellular boundaries. There was also a heavy accumulation of neutrophils surrounding the portal vein. These neutrophils act as an indicator of the occurrence of cell damage as they are absent in normal healthy tissues. The hepatocytes are disrupted and sinusoids are damaged as well.




Figure 3: Hematoxylin and eosin staining, X400: (A) Normal control rat liver section (Group-I): Normal histological findings in the liver parenchyma; (B) Liver section of the rat intoxicated with Carbon tetrachloride (Group-II): Indicated variable degree of bridging necrosis of hepatocytes, most marked in centrilobular and mononuclear cellular infiltrate in the lobule. Mild degree of liver cell necrosis is seen as ballooning degeneration; (C) Liver section of the rat treated with silymarin and intoxicated with carbon tetrachloride (Group-V) and (D) Liver section of the rat treated with 400 mg/kg of EEF-PG intoxicated with carbon tetrachloride (Group-IV): Showing centrilobular regeneration with restoration of c.v, ss and hepatocytes with mild necrosis. C.V: Central vein, V.C: Vacuole, S.S: Sinusoidal spaces, H.C: Hepatocytes.




Figure 4: Histopathology report. (A) Normal control rat liver section (Group-I): Showed a normal structure of the liver; **(B) Liver section of the rat intoxicated with Carbon tetrachloride (Group-II):** Showed portal inflammation and panacinar necrosis; **(C) Liver section of the rat treated with silymarin and intoxicated with carbon tetrachloride (Group-V):** Showed minimal portal inflammation and their lobular architecture was normal; **(D) Liver section of the rat treated with 200 mg/kg of EEF-PG and intoxicated with carbon tetrachloride (Group-III):** Showed minimal inflammation with moderate portal triditis, moderate necrotic debris and their lobular architecture was normal.

CONCLUSION

From the above experimental data, here I concluded that the EEF-PG contained various bioactive molecules which were isolated by ESI-MS-MS and executed moderate to good hepatoprotective activity. When compared with standard drug silymarin it displayed that EEF-PG had the ability to restore and regenerate the CCl_4 induced hepatocytes due to the presence of diverse biomolecules.

REFERENCES

1. "Does a larger pomegranate yield more seeds?". Aqua Phoenix.
2. Floridata: *Punica granatum*.
3. Nutrition data for raw pomegranate, Nutritiondata.com.
4. Schubert SY, Lansky EP, Neeman I (July 1999). "Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids". *J Ethnopharmacol*, 66(1): 11–17. doi:10.1016/S0378-8741(98)00222-0. PMID 10432202.
5. Aviram M, Rosenblat M, Gaitini D et al. (June 2004). "Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation". *Clin Nutr*, 23(3): 423–33. doi:10.1016/j.clnu.2003.10.002. PMID 15158307.
6. Esmailzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L (2004). "Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia". *J Med Food*, 7(3): 305–8. doi:10.1089/1096620041938623. PMID 15383223.
7. Kaplan M, Hayek T, Raz A et al. (1 August 2001). "Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis". *J Nutr.*, 131(8): 2082–9. PMID 11481398.
8. Aviram M, Dornfeld L, Rosenblat M et al. (May 2000). "Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice". *Am. J. Clin. Nutr.*, 71(5): 1062–76. PMID 10799367. Retrieved 2011-03-24.
9. Aviram M, Dornfeld L (September 2001). "Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure". *Atherosclerosis*, 158(1): 195–8. doi:10.1016/S0021-9150(01)00412-9. PMID 11500191.
10. Neurath AR, Strick N, Li YY, Debnath AK (2004). "Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide". *BMC Infect. Dis.*, 4: 41. doi:10.1186/1471-2334-4-41. PMC 533885. PMID 15485580.
11. Menezes SM, Cordeiro LN, Viana GS (2006). "Punica granatum (pomegranate) extract is active against dental plaque". *Journal of herbal pharmacotherapy*, 6(2): 79–92. doi:10.1300/J157v06n02_07. PMID 17182487.
12. Seeram NP, Aronson WJ, Zhang Y et al. (September 2007). "Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland". *J. Agric. Food*

- Chem.*, 55(19): 7732–7. doi:10.1021/jf071303g. PMID 17722872.
13. "NIH-listed human clinical trials on pomegranate". Clinicaltrials.gov. Retrieved, 2013-11-19.
 14. "Pomegranate juice intake enhances salivary testosterone levels and improves mood and well being in healthy men and women". Endocrine-abstracts.org. Retrieved, 2013-07-07.
 15. Raj. K. Bansal, Laboratory manual of organic chemistry, 5th revised edition, 238-239.
 16. P.C Dandiya, P.K. Sharma, Bio-chemistry and clinical pathology, second edition, PP- 17-18, 24, 47-48.
 17. Dr. G. Devala Rao, A Manual of Practical Biochemistry, 17.
 18. Jaswant Kaur, PV Chemistry of Natural Products, 2010 edition, PP-113-114, 116, 344-346, 381.
 19. Zhishen J, Mengcheng T, Jianming W. The determination of flavonoid contents in mulberry and their scavenging effects on superoxide radicals. *Food Chem.*, 1999; 64: 555-559.
 20. Tzulker R, Glazer I, Bar-Ilan I, Holland D, Aviram M, Amir R. Antioxidant activity, polyphenol content and related compounds in different fruit juices and homogenates prepared from 29 different pomegranate accessions. *J Agri Food Chem.*, 2007; 55: 9559–9570.
 21. Borges G, Mullen W, Crozier A. Comparison of the polyphenolic composition and antioxidant activity of European commercial fruit juices. *Food Func.*, 2010; 1: 73-83.
 22. Barros L, Dueñas M, Dias M, Sousa MJ, Santos-Buelga C, Ferreira I. Phenolic profiles of in vivo and in vitro grown *Coriandrum sativum* L. *Food Chem.*, 2012; 132: 841–848.
 23. Li Y, Guo C, Yang J, Wei J, Xu J, Cheng S. Evaluation of antioxidant properties of pomegranate peel extract in comparison with pomegranate pulp extract. *Food Chem.*, 2006; 96: 254–260.
 24. Abdel Moneim AE. Antioxidant activities of *Punica granatum* (pomegranate) peel extract on brain of rats. *J Med Plant Res.*, 2012; 6(2): 195-199.
 25. Apak R, Guclu K, Demirata B, Ozyurek M, Celik S, Bektasoglu B, et al. Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay, *Mol.*, 2007; 12: 1496–1547.
 26. Galati G, O'Brien P. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. *Free Radical Biol Med.*, 2004; 37: 287–303.
 27. Payet B, Shum Cheong Sing A, Smadja J. Assessment of antioxidant activity of cane brown sugars by ABTS and DPPH radical scavenging assays: determination of their polyphenolic and volatile constituents. *J Agri food chem.*, 2005; 53: 10074–10079.
 28. Naveena B, Sen A, Kingsly R, Singh D, Kondaiah N. Antioxidant activity of pomegranate rind powder extract in cooked chicken patties. *Int J Food Sci Technol.*, 2008a; 43: 1807-1812.
 29. Kulkarni A, Aradhya S, Divakar S. Isolation and identification of a radical scavenging antioxidant - punicalagin from pith and carpellary membrane of pomegranate fruit. *Food Chem.*, 2004; 87: 551–557.
 30. Chuu C, Lin H, Ciaccio M, Kokontis J, Hause R, Hiipakka R, et al. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of P70 S6K and Akt signaling network. *Cancer Prev Res.*, 2012; 5: 788-97.
 31. Shibani M, Al-Otaibi M, Al-Zoreky N. Antioxidant Activity of pomegranate (*Punica granatum* L.) fruit peels. *Food Nutri Sci.*, 2012; 3: 991-996.
 32. "OECD guidelines – 423" for testing of chemicals, 2001; 1-14.
 33. Garrat DC. *The Quantitative Analysis of Drugs*, Japan, Chapman and Hall, 1964; 456.